Syros Pharmaceuticals (SYRS): Wedbush Reiterates Outperform Rating Today, Has a Target of $13/Share

March 14, 2018 - By Vivian Currie

 Syros Pharmaceuticals (SYRS): Wedbush Reiterates Outperform Rating Today, Has a Target of $13/Share

Syros Pharmaceuticals (SYRS) Rating Reaffirmed

In a report revealed to clients and investors this morning, Wedbush maintained their Outperform rating on Syros Pharmaceuticals (SYRS) shares. The PT would suggest a possible upside of 5.78 % from firm’s last close price.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Ratings Coverage

Among 7 analysts covering Syros Pharmace… (SYRS), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Syros Pharmace… has $30 highest and $1000 lowest target. $19.40’s average target is 57.85% above currents $12.29 stock price. Syros Pharmace… had 15 analyst reports since July 18, 2016 according to SRatingsIntel. JMP Securities upgraded the stock to “Market Outperform” rating in Thursday, September 28 report. On Friday, July 21 the stock rating was maintained by Oppenheimer with “Buy”. The firm earned “Buy” rating on Monday, August 21 by Oppenheimer. The stock of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) earned “Buy” rating by Cowen & Co on Wednesday, August 9. The rating was maintained by Oppenheimer on Monday, June 12 with “Buy”. The firm has “Hold” rating given on Monday, June 19 by H.C. Wainwright. The rating was maintained by Roth Capital with “Hold” on Wednesday, November 1. The stock of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) earned “Outperform” rating by Wedbush on Tuesday, March 13. PiperJaffray reinitiated the stock with “Overweight” rating in Tuesday, October 31 report. The firm has “Market Perform” rating by JMP Securities given on Thursday, August 10.

The stock decreased 1.44% or $0.18 during the last trading session, reaching $12.29. About 200,834 shares traded. Syros Pharmaceuticals, Inc. (SYRS) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) to report earnings on May, 21. They expect $-0.34 earnings per share, up 30.61 % or $0.15 from last year’s $-0.49 per share. After $-0.58 actual earnings per share reported by Syros Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -41.38 % EPS growth.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing treatments for cancer and immune-mediated diseases, and building a pipeline of gene control medicines. The company has market cap of $395.59 million. The Company’s lead drug candidates are SY-1425, a selective RARa agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. It currently has negative earnings. The firm was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.

More notable recent Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) news were published by: which released: “Incyte and Syros Announce Global Target Discovery and Validation Collaboration …” on January 08, 2018, also with their article: “Syros Announces Proposed Offering of Common Stock” published on January 30, 2018, published: “5 Keys To Understanding Syros Pharma’s ASH Presentation” on December 11, 2017. More interesting news about Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) were released by: and their article: “Free Research Reports on These Biotech Stocks — Seattle Genetics, Spectrum …” published on February 27, 2018 as well as‘s news article titled: “Form 8-K Syros Pharmaceuticals, For: Mar 07” with publication date: March 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.